Skip to main content
Premium Trial:

Request an Annual Quote

NEWSBRIEF: AnVil Gets SBIR Grants To Develop Cancer Drug Software

NEW YORK, May 7-Massachusetts bioinformatics company AnVil said today that it has received two Small Business Innovation Research grants to develop software for cancer drug developers.


The grants were awarded by the National Institutes of Health  for $99,225 and $98,328.


AnVil will use one grant to merge quantitative cluster comparison metrics with new visualization technologies. The company will then apply this new software tool to a National Cancer Institute compound data set.


With the second grant, AnVil will develop new high-dimensional visualization methods for data mining and cancer data analysis.


AnVil, based in Burlington, Mass., is privately owned.


For further information, see the company's website.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.